Terns Pharmaceuticals(US:TERN)2026-03-09 18:42Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, has transitioned from a metabolic company to focus on chronic myeloid leukemia (CML) with its lead asset, TERN-701, an allosteric BCR-ABL inhibitor [3][4] Core Insights - Efficacy of TERN-701: Data presented at ASH showed TERN-701 achieved a 75% major molecular response (MMR) rate at 24 weeks, significantly higher than competitors [20][31]. - Safety Profile: TERN-701 has a differentiated safety profile with no observed signals for hypertension or pancreatic toxicity, which are concerns with other treatments like asciminib [20][70]. - Convenience: TERN-701 can be taken without regard to food, unlike some competitors that require fasting [3][20]. CML Market Dynamics - Current Treatment Landscape: CML was previously fatal before BCR-ABL inhibitors like imatinib were introduced. However, about 75% of patients become refractory to imatinib, leading to a need for better therapies [5][6]. - Scemblix's Market Position: Scemblix has captured about 25% of the front-line market and over 50% in second-line plus patients, being recognized as the safest therapy available [6][8]. - Patient Population: Approximately 17,000 new patients are diagnosed with CML annually in the G7, with an additional 13,000 in the second-line and second-line plus population [44][48]. Competitive Landscape - Comparison with Asciminib: TERN-701 is positioned to outperform asciminib, especially in patients who are refractory to it. The efficacy in asciminib refractory patients is seen as a key differentiator [49][60]. - Market Potential: Analysts estimate the market for CML treatments could reach $4 billion, with TERN-701 expected to capture significant market share due to its superior profile [65][66]. Regulatory and Development Strategy - Pivotal Trials: Terns is preparing for pivotal trials in the second-line plus population and is also planning a frontline study, potentially starting in 2027 [85][88]. - Enrollment Success: Enrollment for ongoing studies has been strong, with expectations to fully enroll the CARDINAL study this year [88]. Additional Considerations - Patient Switching: There is a prevalent population of about 100,000 patients who may switch to TERN-701 as better therapies become available [48]. - Market Access Challenges: Some patients may not have access to newer therapies due to cost concerns, with generics still playing a role in treatment decisions [68][69]. Conclusion - Terns Pharmaceuticals is well-positioned in the CML market with TERN-701, which shows promising efficacy and safety compared to existing therapies. The company is actively pursuing regulatory pathways to bring this innovative treatment to market while navigating competitive dynamics and patient access challenges.